Metformin induces a shift from glycolysis to fatty acid oxidation in cardiac hypertrophy via PHB1

Abstract

•Identifying therapies that arrest the metabolic shift from FAO to glycolysis in cardiac hypertrophy (CH) may prevent heart failure.•It is unknown whether metformin can be used as a therapy to arrest metabolic shift in CH.•Prohibitin 1 (PHB1), a mitochondrial resident improves mitochondrial health and functioning in CH.•We asked whether metformin induces a shift from glycolysis to FAO in ISO-induced hypertrophy in cardiomyoblasts, H9C2 cells via PHB1.•We observed that metformin induces a shift from glycolysis to FAO and reduces hypertrophy in ISO-treated H9C2 cells.•Metformin induces and stabilizes PHB1 increasing FAO.•Metformin may be considered a therapy to ameliorate CH.